Browsing Research Articles (Nuclear Medicine) by Subject "225Ac-PSMA-617"

Now showing items 1-3 of 3

Advances in PSMA alpha theragnostics

Vorster, Mariza; Sathekge, Mike Machaba (Elsevier, 2024-07)

Alpha theranostics offer an attractive alternative form of therapy, which has best been investigated and documented with 225Ac-PSMA in patients with prostate cancer. Advantages offered by targeted alpha therapy include ...
mCRPC patients receiving 225Ac-PSMA-617 therapy in the post-androgen deprivation therapy setting : response to treatment and survival analysis

Sathekge, Mike Machaba; Bruchertseifer, Frank; Vorster, Mariza; Lawal, Ismaheel Opeyemi; Knoesen, Otto; Mahapane, Johncy; Davis, Cindy; Mdlophane, Amanda; Maes, Alex; Mokoala, Kgomotso M.G.; Mathabe, Kgomotso; Van de Wiele, Christophe; Morgenstern, Alfred (Society of Nuclear Medicine, 2022-10)

Please read abstract in the article.
Predictors of overall and disease-free survival in metastatic castration-resistant prostate cancer patients receiving 225Ac-PSMA-617 radioligand therapy

Sathekge, Mike Machaba; Bruchertseifer, Frank; Vorster, Mariza; Lawal, Ismaheel Opeyemi; Knoesen, Otto; Mahapane, Johncy; Davis, Cindy; Reyneke, Florette; Maes, Alex; Kratochwil, Clemens; Lengana, Thabo; Giesel, Frederik L.; Van de Wiele, Christophe; Morgenstern, Alfred (Society of Nuclear Medicine, 2020-01)

Metastatic prostate carcinoma overexpresses prostate-specific membrane antigen (PSMA), making this antigen a suitable target for radioligand therapy of the disease. Here we report on our experience with a series of 73 ...

Now showing items 1-3 of 3

Search UPSpace